MedPath

南京恒生制药有限公司

Ownership
-
Established
1995-12-27
Employees
-
Market Cap
-
Website
http://www.hencer.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

61

NMPA:61

Drug Approvals

Sevelamer Carbonate for Suspension

Product Name
碳酸司维拉姆干混悬剂
Approval Number
国药准字H20253566
Approval Date
Mar 4, 2025
NMPA

Sevelamer Carbonate for Suspension

Product Name
碳酸司维拉姆干混悬剂
Approval Number
国药准字H20244815
Approval Date
Sep 3, 2024
NMPA

Ropinirole Hydrochloride Sustained-release Tablets

Product Name
盐酸罗匹尼罗缓释片
Approval Number
国药准字H20244677
Approval Date
Aug 20, 2024
NMPA

Avatrombopag Maleate Tablets

Product Name
马来酸阿伐曲泊帕片
Approval Number
国药准字H20244403
Approval Date
Jul 9, 2024
NMPA

Rivaroxaban Tablets

Product Name
利伐沙班片
Approval Number
国药准字H20223348
Approval Date
May 31, 2022
NMPA

Rivaroxaban Tablets

Product Name
利伐沙班片
Approval Number
国药准字H20223347
Approval Date
May 31, 2022
NMPA

Trimetazidine Hydrochloride Tablets

Product Name
盐酸曲美他嗪片
Approval Number
国药准字H20073969
Approval Date
Jan 5, 2022
NMPA

Sodium Ibandronate Injection

Product Name
伊班膦酸钠注射液
Approval Number
国药准字H20217088
Approval Date
Oct 15, 2021
NMPA

Trimetazidine Dihydrochloride

Product Name
盐酸曲美他嗪
Approval Number
国药准字H20056629
Approval Date
Apr 21, 2021
NMPA

Cinacalcet Hydrochloride Tablets

Product Name
盐酸西那卡塞片
Approval Number
国药准字H20213111
Approval Date
Feb 2, 2021
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.